Imagine Having Your Own Personal Psychiatrist Dr AI-Jane at Home! You Too Deserve Peace.
Ari Massoudi
I do stuff enabling Mankind to live longer, stronger and smarter ?????????=>??
The Unlikely Discovery of Lithium: A Tale of Guinea Pigs and Human Resilience
In the annals of medical history, few stories are as captivating and serendipitous as the discovery of lithium. Unlike the meticulously designed small-molecule drugs we often encounter, lithium stands apart. It's an element—a simple, unassuming metal that has become a cornerstone in the treatment of mental illnesses. Lithium is not just a chemical; it's a cultural icon, a stigmatized savior, and the title of one of Nirvana's most haunting songs. But its journey to becoming a lifeline for those suffering from bipolar disorder is a tale of chance, resourcefulness, and a physician's unwavering dedication.
The Birth of a Medical Marvel
Lithium, the third element on the periodic table, was discovered in 1817. Its name is derived from the Greek word "lithos," meaning stone. But it wasn't until nearly a century and a half later that its true potential was unveiled, thanks to the efforts of an Australian physician named John F. J. Cade.
Cade, the son of a World War I veteran, grew up in a world where mental health was a taboo subject. His father, David Cade, suffered from "war weariness" and sought solace in the mental hygiene department of a local hospital. This backdrop shaped young John's future. He excelled in his medical studies at Melbourne University, graduating at the tender age of 21. His life took a dramatic turn during World War II, where he served as a physician and was later held as a prisoner of war in Singapore's Changi Camp.
Of Guinea Pigs and, Well, Guinea Pigs
While interned at Changi, Cade observed that all his psychiatric patients who died had some level of pathology on autopsy. This led him to believe that a toxic agent was behind their conditions, particularly in those with manic-depressive illnesses. He hypothesized that the body produced excess amounts of a chemical agent in mania and not enough in melancholia.
Returning home, Cade became the senior medical officer at a war veterans repatriation mental hospital in Bundoora. Despite the lack of a proper research laboratory, he began experimenting with guinea pigs in 1947. His lab? A woodshed or an abandoned kitchen on the hospital grounds. His test subjects? The urine of manic patients, which he injected into the guinea pigs to observe their reactions.
Cade's experiments were crude but effective. He found that the urine of manic patients was especially toxic to the guinea pigs, causing tremors, loss of coordination, paralysis, and seizures. To further investigate, he injected the guinea pigs with solutions of urea, uric acid, and creatine. The guinea pigs injected with urea died, but those injected with urea and creatine did not suffer seizures, suggesting creatine had a protective effect.
The Serendipitous Choice
Serendipity played a pivotal role in Cade's discovery. Uric acid is notoriously hard to dissolve in water, so Cade chose lithium urate, the most soluble of the urates, to dissolve a sample of urea. When he injected the guinea pigs with a solution containing lithium urate, he observed a dramatic decrease in toxicity. Thinking the lithium ion was the protective agent, he tried the experiment again using lithium carbonate. All ten guinea pigs injected with the solution survived, while five out of ten injected with urea alone died.
From Guinea Pigs to Humans
Cade's results were promising, but he needed to prove the lithium salts were safe for humans. In a remarkable act of self-experimentation, he ingested the lithium salts at test dosages and found no issues. Satisfied with the safety, he set out to treat a group of nineteen patients with lithium citrate. Among them was "W. B.," a 51-year-old male who lived in a chronic state of mania for the past five years. Within three weeks of treatment, W. B. was allowed within the convalescent ward and was soon discharged from the hospital on a maintenance dose of lithium carbonate.
The Slow Journey to Acceptance
Cade's groundbreaking paper, "Lithium Salts in the Treatment of Psychotic Excitement," was published in the September 1949 edition of the Medical Journal of Australia. However, it took decades for the scientific community to recognize its merit. This delay was partly due to a lithium chloride scare in the United States, where lithium chloride was used as a table salt substitute, leading to tragic consequences.
The Critique of Serendipity and the Promise of AI
While Cade's discovery was a triumph of serendipity and empirical practice, it also highlights the limitations of such methods. The path to lithium's acceptance was long and fraught with setbacks. In contrast, the advent of artificial intelligence (AI) in medicine promises a more systematic and efficient approach to drug discovery. AI can analyze vast amounts of data, identify patterns, and predict outcomes with a precision that human intuition alone cannot match.
A Different History with AI
Imagine if Cade had access to AI. The years of trial and error, the risks taken with self-experimentation, and the slow journey to acceptance could have been drastically shortened. AI could have analyzed the data from Cade's experiments, identified the protective effects of lithium, and predicted its potential as a treatment for bipolar disorder much faster. The history of lithium would have been a story of precision and efficiency rather than serendipity and chance.
If you're interested by AI-driven drug discovery ??????
ITW Dr. Ivan De Weber, PhD - Cofounder-CEO at Cortex Discovery
Exciting news! ?? Join us for the next episode of our LinkedIn Live podcast featuring Dr. Ivan De Weber, PhD , co-founder and CEO of Cortex Discovery , a groundbreaking startup revolutionizing drug discovery through AI!
?? From Academia to AI-Powered Drug Discovery
Dr. de Weber's journey is nothing short of inspiring. We'll explore his transition from cellular biology and pharmaceutical bioinformatics to founding a company at the cutting edge of AI-driven drug discovery. Learn how his lifelong quest for longevity research led to the creation of Cortex Discovery.
?? Unveiling Cortex Discovery's Innovative Approach
Discover how Cortex Discovery is disrupting preclinical drug discovery across all therapeutic areas with their proprietary AI models. We'll delve into:
? Their foundation model for drug property predictions
? The vast database of 750 million data points powering their deep learning system
? Recent breakthroughs, including the first AI-discovered compound proven to extend lifespan in a whole organism
?? Business Insights and Future Outlook
Get an insider's perspective on:
? Cortex Discovery's unique business model and collaboration opportunities
? Challenges faced in the AI-driven drug discovery landscape
? The company's vision for the future of longevity research and pharmaceutical development
This episode is a must-watch for:
? Biotech and pharmaceutical executives
? Investors in the life sciences sector
? Academic researchers in pharmaceutical chemistry, longevity biology, and clinical medicine
? Anyone interested in the intersection of AI and drug discovery
Don't miss this opportunity to gain valuable insights into the future of AI-powered drug discovery and longevity research. Tune in to our LinkedIn Live podcast and be part of the conversation shaping the future of medicine!